领扣型人工角膜移植术治疗高危移植角膜盲的多中心临床试验
本研究为病例系列研究,前瞻性连续纳入2019年7月至2020年1月中国5家医院的高危移植角膜盲患者37例(37只眼),行领扣型人工角膜(c-bKPro)移植术。术后6个月83.8%术眼视力≥0.05,12个月81.8%;12个月人工角膜在位率100%,并发症发生率较低。结论认为该手术对中国高危移植角膜盲安全有效。
要点
- 37只高危移植角膜盲眼行c-bKPro移植,术后6个月83.8%、12个月81.8%术眼视力≥0.05。
- 术后12个月人工角膜在位率100%,并发症以光学镜柱后膜和持续性角膜上皮缺损最常见(各16.1%)。
- 合并青光眼11只眼中,术后12个月6只眼视力≥0.05。
核心结论
- 领扣型人工角膜移植术治疗中国高危移植角膜盲安全且有效,术后多数患者可获得较好视力,并发症发生率较低。
研究设计与样本
- 病例系列研究,前瞻性连续纳入2019年7月至2020年1月山东第一医科大学附属眼科医院、解放军总医院眼科医学部、中山大学中山眼科中心、复旦大学附属眼耳鼻喉科医院眼科和温州医科大学附属眼视光医院拟行c-bKPro移植的高危移植角膜盲患者。
- 共纳入37例(37只眼),男性32例、女性5例,年龄27~72岁;术后随访12个月。
主要发现
- 术后6个月83.8%术眼视力≥0.05,术后12个月81.8%术眼视力≥0.05。
- 合并青光眼11只眼,术后12个月6只眼视力≥0.05。
- 术后12个月c-bKPro在位率100%。
- 术后并发症包括光学镜柱后膜形成5只眼(16.1%)、持续性载体角膜上皮缺损5只眼(16.1%)、黄斑水肿4只眼(12.9%)、新发青光眼4只眼(12.5%,包括因新发青光眼术后3个月退出研究1只眼)、无菌性载体角膜融解2只眼(6.5%)、继发无菌性玻璃体炎1只眼(3.2%)、感染性角膜炎1只眼(3.2%)。
关键数值与推荐
- 以视力≥0.05为标准计算脱盲率并评定治疗有效性。
- 记录术后并发症情况、人工角膜在位情况以评定手术安全性。
- 手术适应证:角膜移植术后植片混浊21只眼(56.8%)、眼部化学烧伤8只眼(21.6%)、眼部热烧伤5只眼(13.5%)、不明原因角膜混浊2只眼(5.4%)、角膜融解穿孔1只眼(2.7%)。
临床怎么用
- 原文结论认为c-bKPro移植术治疗中国高危移植角膜盲安全且有效,术后多数患者可获得较好视力,并发症发生率较低。
局限性
- 2只眼于术后3个月退出研究,35只眼完成术后6个月随访,31只眼完成术后12个月随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficiency and safety of collar-button type keratoprosthesis (c-bKPro) implantation for corneal blindness in high-risk transplantation in China. Methods: It was a case series study. High-risk corneal blind patients who planned to undergo c-bKPro implantation were prospectively and continuously enrolled in the Eye Hospital of Shandong First Medical University, Ophthalmology Division of Chinese PLA General Hospital, Zhongshan Ophthalmic Center, Department of Ophthalmology in Eye & ENT Hospital of Fudan University, and Eye Hospital of Wenzhou Medical University from July 2019 to January 2020. The cure for blindness and surgical success were assessed based on visual acuity (VA)≥0.05. The complications and keratoprosthesis retention rate were recorded to determine the safety of the surgery. Results: Thirty-seven subjects (eyes) were included, of which 32 were male and 5 were female, aged 27 to 72 years old. The indications of c-bKPro implantation were corneal graft failure (21 eyes, 56.8%), chemical injury (8 eyes, 21.6%), thermal burn (5 eyes, 13.5%), unexplained corneal opacity (2 eyes, 5.4%), and corneal perforation (1 eye, 2.7%). Two patients withdrew from the clinical trial at 3 months postoperatively. Thirty-five patients were followed up for 6 months, and 31 were followed up for 12 months. The VA was ≥0.05 in 83.8% of eyes at 6 months and in 81.8% of eyes at 12 months. Among the 11 eyes diagnosed with concurrent glaucoma, 6 eyes achieved a VA of ≥0.05. At 12 months, the c-bKPro retention rate was 100%. The surgical complications included retroprosthetic membrane formation (5 eyes, 16.1%), persistent corneal epithelial defects (5 eyes, 16.1%), macular edema (4 eyes, 12.9%), new-onset glaucoma (4 eyes, 12.5%; including one eye withdrawn from the study at 3 months), sterile corneal melting (2 eyes, 6.5%), sterile vitritis (1 eye, 3.2%), and infectious keratitis (1 eye, 3.2%). Conclusions: C-bKPro implantation is an effective and safe option for treating corneal blindness in high-risk transplantation in China. Improved visual outcomes could be achieved in most cases, with a relatively low incidence of postoperative complications. 目的: 评价领扣型人工角膜移植术治疗高危移植角膜盲的有效性和安全性。 方法: 病例系列研究。前瞻性连续收集2019年7月至2020年1月在山东第一医科大学附属眼科医院、解放军总医院眼科医学部、中山大学中山眼科中心、复旦大学附属眼耳鼻喉科医院眼科和温州医科大学附属眼视光医院就诊且符合条件、拟行领扣型人工角膜移植术的高危移植角膜盲患者。术后随访12个月,观察患者的术后视力,以视力≥0.05为标准计算脱盲率并评定治疗的有效性;记录术后并发症情况、人工角膜在位情况,以评定手术的安全性。 结果: 37例(37只眼)患者纳入研究,男性32例,女性5例;年龄范围为27~72岁。角膜移植手术后角膜植片混浊21只眼(56.8%),眼部化学烧伤8只眼(21.6%),眼部热烧伤5只眼(13.5%),不明原因角膜混浊2只眼(5.4%),角膜融解穿孔1只眼(2.7%)。2只眼于术后3个月退出研究,35只眼完成术后6个月随访,31只眼完成术后12个月随访。术后6个月83.8%术眼视力≥0.05,术后12个月81.8%术眼视力≥0.05。合并青光眼11只眼,术后12个月6只眼视力≥0.05。术后12个月领扣型人工角膜的在位率为100%;5只眼(16.1%)光学镜柱后膜形成,5只眼(16.1%)出现持续性载体角膜上皮缺损,4只眼(12.9%)发生黄斑水肿,4只眼(12.5%)新发青光眼(包括因新发青光眼术后3个月退出研究1只眼),2只眼(6.5%)出现无菌性载体角膜融解,继发无菌性玻璃体炎、感染性角膜炎各1只眼(3.2%)。 结论: 领扣型人工角膜移植术治疗高危移植角膜盲安全且有效,术后多数患者可获得较好视力,且并发症发生率较低。.
引用
- Zhang T, Wang LL, Gu JJ, et al. [A multicenter clinical trial of collar-button type keratoprosthesis implantation for the treatment of corneal blindness in high-risk transplantation]. Zhonghua Yan Ke Za Zhi. 2023. PMID: 37012589. doi:10.3760/cma.j.cn112142-20221103-00565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。